Cargando…
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
Personalized cancer medicine aims to accurately predict the response of individual patients to targeted therapies, including tyrosine kinase inhibitors (TKIs). Clinical implementation of this concept requires a robust selection tool. Here, using both cancer cell lines and tumor tissue from patients,...
Autores principales: | Labots, Mariette, Gotink, Kristy J, Dekker, Henk, Azijli, Kaamar, van der Mijn, Johannes C, Huijts, Charlotte M, Piersma, Sander R, Jiménez, Connie R, Verheul, Henk M W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192072/ https://www.ncbi.nlm.nih.gov/pubmed/27980342 http://dx.doi.org/10.1038/emm.2016.114 |
Ejemplares similares
-
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015) -
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009) -
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015) -
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018) -
Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer
por: van der Mijn, Johannes C., et al.
Publicado: (2014)